期刊
AMERICAN JOURNAL OF SURGERY
卷 221, 期 6, 页码 1128-1134出版社
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjsurg.2021.04.001
关键词
Ampullary cancer; Hepatopancreatobiliary surgery; Pancreatoduodenectomy; Cancer outcomes; Adjuvant therapy
类别
Pathologic subtype and receipt of adjuvant therapy may impact survival in ampullary cancer patients, but stage remains the primary determinant of survival.
Background: Outcomes in ampullary cancer (AC) may differ by pathologic subtype. No guidelines exist for the administration of adjuvant therapy (AT). We sought to evaluate the effect of subtype and AT on survival. Methods: An institutional review of patients undergoing resection for AC from 2008-17 was performed. Recurrence-free (RFS) and overall survival (OS) were assessed by Kaplan-Meier and Cox proportional hazards modeling. Results: Of 53 patients, two-thirds (62%) were stage III. Histologic subtype was evenly split between intestinal and pancreatobiliary (43% and 40%). Half of patients received AT. RFS and OS were 25 (95% CI 16-32) and 41 (CI 22-60) months, respectively, without significant difference by subtype. Stage II/III disease was associated with worse OS (HR 3.7, P = 0.03), which was improved with receipt of AT (HR 0.44, P < 0.05). Conclusion: Stage is the primary determinant of survival in AC, which may be improved with AT. (C) 2021 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据